Reddy’s calls on FDA to inspect at Duvvada

Dr Reddy’s Laboratories has requested the US Food and Drug Administration (FDA) schedule an inspection of the firm’s oncology formulation manufacturing facility in Duvvada, Andhra Pradesh, India, as part of the firm’s ongoing attempts to resolve agency concerns at the firm’s two warning letter-stricken plants.

Dr Reddy’s Laboratories has requested the US Food and Drug Administration (FDA) schedule an inspection of the firm’s oncology formulation manufacturing facility in Duvvada, Andhra Pradesh, India, as part of the firm’s ongoing attempts to resolve agency concerns at the firm’s two warning letter-stricken plants.

Alongside the Duvvada facility, Reddy’s active pharmaceutical ingredient (API) manufacturing facility in Srikakulam, Andhra Pradesh, continues to be restrained by...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Manufacturing

More from Business